Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

37
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

31
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

20
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
20
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

27
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

22
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Course and Predictors of Heart Failure in Asymptomatic Obstructive Hypertrophic Cardiomyopathy.

Journal of the American Heart Association·2026
Same author

Influence of Genotype on Cardiac Phenotype in Pediatric Hypertrophic Cardiomyopathy.

Circulation. Genomic and precision medicine·2026
Same author

Assessing the need for cardioverter defibrillator implantation in hypertrophic cardiomyopathy: patient association's perspectives.

European heart journal·2026
Same author

Invasive exercise hemodynamics in obstructive and non-obstructive hypertrophic cardiomyopathy.

Journal of applied physiology (Bethesda, Md. : 1985)·2026
Same author

Cardiac mechanopathies: regional stress maldistribution as a primary determinant of myocardial disease.

Heart (British Cardiac Society)·2026
Same author

Evolving Epidemiology of Cardiomyopathies at a National Referral Centre: a 30-Year Longitudinal Study.

European heart journal. Quality of care & clinical outcomes·2026
Same journal

Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.

Journal of clinical medicine·2026
Same journal

Surgical and Transcatheter Approach of a Failed Mitral Valve Repair: A Comprehensive Review on Selecting the Most Suitable Approach.

Journal of clinical medicine·2026
Same journal

Hybrid Metaheuristic Feature Selection for Breast Cancer Detection in Digital Mammography: A Feasibility Study with Nested Validation, Benchmarking, and External Stress Testing.

Journal of clinical medicine·2026
Same journal

Identity Transformation and the Role of Accountability in Recovery from Problematic Pornography Use: A Phenomenological-Hermeneutical Study.

Journal of clinical medicine·2026
Same journal

Does Early Surgical Treatment in Degenerative Cervical Myelopathy Have a Favorable Clinical Outcome and Impact on Quality of Life?

Journal of clinical medicine·2026
Same journal

Shear Wave Elastography in Musculoskeletal Imaging: A Narrative Review.

Journal of clinical medicine·2026
See all related articles

Related Experiment Video

Updated: Aug 22, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.1K

Microvascular Dysfunction in Hypertrophic Cardiomyopathy.

Francesco Pelliccia1, Franco Cecchi2, Iacopo Olivotto3

  • 1Department of Cardiovascular Sciences, Sapienza University, 00166 Rome, Italy.

Journal of Clinical Medicine
|November 11, 2022
PubMed
Summary
This summary is machine-generated.

Myocardial ischemia, driven by coronary microvascular dysfunction (CMD), is key in hypertrophic cardiomyopathy (HCM). Early non-invasive assessment of CMD is crucial for managing heart failure and sudden cardiac death risk in HCM patients.

Keywords:
hypertrophic cardiomyopathymicrocirculationmyocardial ischemia

More Related Videos

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.4K
Non-invasive Assessment of Microvascular and Endothelial Function
05:41

Non-invasive Assessment of Microvascular and Endothelial Function

Published on: January 29, 2013

16.3K

Related Experiment Videos

Last Updated: Aug 22, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.1K
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.4K
Non-invasive Assessment of Microvascular and Endothelial Function
05:41

Non-invasive Assessment of Microvascular and Endothelial Function

Published on: January 29, 2013

16.3K

Area of Science:

  • Cardiology
  • Cardiovascular Pathophysiology

Background:

  • Myocardial ischemia is a significant feature of hypertrophic cardiomyopathy (HCM), influencing heart failure (HF) and sudden cardiac death (SCD).
  • Coronary microvascular dysfunction (CMD), without epicardial coronary artery disease, is the primary cause of ischemia in HCM.
  • Assessing microcirculation non-invasively is challenging but vital for understanding HCM pathophysiology.

Purpose of the Study:

  • To highlight the importance of assessing myocardial ischemia and CMD in hypertrophic cardiomyopathy.
  • To emphasize the role of non-invasive multimodality imaging in evaluating microvascular dysfunction.
  • To underscore the necessity of early CMD diagnosis for risk stratification and patient management in HCM.

Main Methods:

  • Utilizing a multimodality approach for detailed assessment of microvascular dysfunction and ischemia.
  • Employing non-invasive diagnostic tools including transthoracic Doppler echocardiography, positron emission tomography, and cardiac magnetic resonance.
  • Integrating diagnostic work-up for myocardial ischemia into the routine management of HCM patients.

Main Results:

  • Non-invasive assessment of CMD using advanced imaging techniques is feasible and recommended for all HCM patients.
  • Myocardial ischemia contributes to cardiac fibrosis, left ventricular remodeling, heart failure, and arrhythmias in HCM.
  • Comprehensive evaluation of ischemia aids in the risk stratification for sudden cardiac death in HCM.

Conclusions:

  • Non-invasive assessment of coronary microvascular dysfunction should be a standard part of HCM evaluation.
  • Early diagnosis and management of myocardial ischemia are critical for improving outcomes in HCM patients.
  • Addressing CMD is a key challenge for improving the prognosis of hypertrophic cardiomyopathy.